The company was established in January 2018 and is the first enterprise in China dedicated to the preclinical CRO evaluation of respiratory disease treatment drugs (with a focus on inhalation preparations). The company was formerly the Zhejiang Respiratory Drug Research Laboratory Team of the former Zhejiang University and the State Food and Drug Administration. The expert team includes national new drug respiratory pharmacology review experts. Former BD General Manager of wuxi AppTec North America, leading figure in China's inhalation drug research and development, and a returned overseas doctoral graduate from a prestigious university, etc. Our team began the preclinical biological evaluation of inhaled drugs in China earlier and has profound knowledge in respiratory pharmacology and immunopharmacology. With accumulated knowledge and rich preclinical evaluation experience in respiratory disease treatment drugs, anti-inflammatory and immune drugs, and inhalation preparations, it is in a leading position in China in the screening and development of new drugs and improved new drugs that can be used for respiratory diseases, anti-inflammatory and immune drugs, and those that can be converted into inhalation preparations. The company now has an outstanding R&D team of over 50 people composed of multi-level scientific and technological talents such as researchers, doctors, masters and undergraduate and junior college students, and is equipped with professional instruments and equipment worth 20 million yuan.